Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Famitinib Adjuvant Therapy in High-Risk Stage II-IIIA NSCLC
NCT05005468Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Camrelizumab + Famitinib with Observation (2 arms). Primary endpoint: Disease-Free Survival. Status: unknown.
02
Drugs
camrelizumabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05005468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005468.